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The innate immune cells sense microbial infection and self-ligands by pathogen rec-
ognition receptors (PRRs), such as toll-like receptors (TLRs) and regulatory receptors 
(RRs), associated with immunoreceptor tyrosine-based activation motif (ITAM). Rapid 
activation and concerted action of PRRs signaling and feedback inhibitory mechanisms 
must be engaged to ensure the host defense functions and to prevent cytotoxicity 
associated with excessive activation. ITAM-associated RRs can generate stimulatory 
or, paradoxically, inhibitory signals. The network of ITAM-associated RR, together with 
TLR-signaling pathways, are responsible for immunogenic or tolerogenic responses of 
macrophages and dendritic cells to their microenvironment. In macrophages, TLR4 sig-
naling is inhibited by low-avidity ligation of ITAM-associated receptors, while high-avidity 
ligation of ITAM-associated receptors results in potentiation of TLR4 signaling together 
with resistance to extracellular cytokine microenvironment signals. In contrast to macro-
phages, TLR7/9 signaling in plasmacytoid DCs (pDCs) is inhibited by high-avidity ligation 
of ITAM-associated RR, while low-avidity ligation does not show any effect. Surprisingly, 
interference of ITAM-associated receptor signaling with TLR pathways has not been 
Abbreviations: BCR, B-cell receptor; BDCA-2, blood dendritic cell antigen 2; BLNK, B-cell linker protein; BTK, Bruton’s 
tyrosine kinase; CD2AP, CD2-associated protein (AP); cDC, conventional dendritic cell; DAG, diacylglycerol; DAP12, DNAX 
activation protein 12; DC, dendritic cell; DCIR, dendritic cell immunoreceptor; ECM, extracellular matrix; FcRs, Fc receptors; 
IC, immune complexes; IL-6, interleukin-6; IFN, interferon; ILT7, immunoglobulin-like transcript; IRAK1/4, interleukin-1 
receptor-associated kinase 1/4; IRF7, interferon-regulatory factor 7; ITAM, immunoreceptor tyrosine-based activation motif; 
ITIM, immunoreceptor tyrosine-based inhibition motif; LLR, lectin-like receptors; MDL-1, myeloid DAP12-associated 
lectin-1; MICL, myeloid C-type lectin-like receptor; Mincle, macrophage-inducible C-type lectin; MAPK, mitogen-activated 
protein kinases; NF-κB, nuclear factor kappa B; pDC, plasmacytoid DC; PI3K, phosphatidylinositol 3-OH kinase; PLCγ2, 
phospholipase Cγ 2; PRRs, pathogen recognition receptors; RF, rheumatoid factor; RGD, arginine–glycyl–aspartic acid motif; 
RRs, regulatory receptors; SHIP, SH2-domain-containing inositol phosphatase-1; R848, Resiquimod; SHP1, SRC-homology-2 
(SH2)-domain-containing protein tyrosine phosphatase 1; TAK1, transforming growth factor β-activated kinase 1; TCR, T-cell 
receptor; TLRs, toll-like receptors; TNF-α, tumor necrosis factor-α; Treg, regulatory T cells T cells; TRAF3/6, tumor necrosis 
factor receptor-associated factors 3 and 6; TREM2, triggering receptor expressed on myeloid cells 2; SYK, spleen tyrosine 
kinase.
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reported in conventional dendritic cells. Here, we present an overview of molecular 
mechanisms acting at the crossroads of TLR and ITAM-signaling pathways and address 
the question of how the high-avidity engagement of the ITAM-associated receptors in 
pDCs inhibits TLR7/9 signaling. Cellular context and spatiotemporal engagement of 
ITAM- and TLR-signaling pathways are responsible for different outcomes of macro-
phage versus pDC activation. While the cross-regulation of cytokine and TLR signaling, 
together with antigen presentation, are the principal functions of ITAM-associated RR in 
macrophages, the major role of these receptors in pDCs seems to be related to inhibition 
of cytokine production and reestablishment of a tolerogenic state following pDC acti-
vation. Pharmacologic targeting of TLR and ITAM signaling could be an attractive new 
therapeutic approach for treatment of chronic infections, cancer, and autoimmune and 
inflammatory diseases related to pDCs.
Keywords: plasmacytoid dendritic cell, conventional dendritic cells, macrophage, toll-like receptors, regulatory 
receptors, immunoreceptor tyrosine-based activation motif-associated receptor, B cell receptor-like signaling
DCs, conventional dendritic cells (cDCs) and plasmacytoid DCs 
(pDCs), inhibits cytokine and TLR7/9 signaling. We compare 
ITAM-mediated inhibitory mechanisms and function of the 
ITAM-associated receptors in these cell types. We focused our 
review on the neglected observation that TLR signaling in pDCs 
is inhibited by high-avidity engagement of the ITAM-associated 
RRs; while in macrophages, it is inhibited by low-avidity engage-
ment of these receptors.
On the basis of this comparison, we assess the functions of the 
ITAM-associated receptors in those cells types. We hypothesize 
that while antigen presentation and cross-regulation of cytokine 
and TLR signaling are the principal functions of ITAM-associated 
receptors in macrophages, the major role of these receptors in 
pDCs is the inhibition of cytokine production and reestablish-
ment of a tolerogenic state following pDC activation.
iMMUNOGeNiC AND TOLeROGeNiC 
ReCePTORS OF DCs
Plasmacytoid DCs are a highly specialized subset of DCs that 
function as sentinels for viral infection and cancer. They are 
responsible for production of type I and III IFNs, IFN-I (namely 
IFN-α, β, and ω) and IFN-III (IFN-λ1, λ2, λ3, and λ4 also called 
IL-29, IL-28A, IL-28B, and IL-28C), pro-inflammatory cytokines, 
and antigen presentation (Figure 1A). pDCs are able to detect 
genetic material of viruses with a subset of nucleotide-sensing 
TLRs localized in the endosomal compartment: TLR7, which 
recognizes single-stranded RNA, and TLR9, which recognizes 
DNA. TLR7 also recognizes synthetic imidazoquinoline compo-
nents, for example Resiquimod (R848), whereas TLR9 recognizes 
synthetic CpG oligonucleotides. Ligation of TLR9 with aggregat-
ing CpG-A oligonucleotides in the early endosomes triggers the 
adaptor protein 3-dependent MyD88-IRF7 pathway that includes 
TLR adaptor MyD88, interleukin-1 receptor-associated kinase 
1/4 (IRAK1/4), tumor necrosis factor receptor-associated factors 
3 and 6 (TRAF3/6), and interferon-regulatory factor 7 (IRF7), and 
that results in the type I IFN production (3, 5, 10, 11) (Figure 1A). 
Activated IRF7, which is constitutively expressed in pDCs, 
iNTRODUCTiON
Macrophages and dendritic cells (DCs) play a major role in initi-
ating and sustaining innate and adaptive immune responses and 
are the nexus at which immune stimulation or suppression occurs 
(1–5). The innate immune cells sense microbial infection and self-
ligands such as damaged or altered self, including dead cells, by 
pathogen recognition receptors (PRRs), such as toll-like receptors 
(TLRs) and lectin-like receptors (LLRs), also called C-type lectin 
receptors (6). Rapid activation and concerted action of PRRs 
signaling is needed to ensure the host defense functions after 
infectious challenge or tissue damage. PRR agonists and secreted 
cytokines and chemokines are the drivers and the major regula-
tors of fine-tuned innate immune responses. Concomitantly, 
feedback inhibitory mechanisms must be engaged to prevent 
cytotoxicity associated with excessive activation of the innate 
immune cells (7). Thus, TLRs that confer functional specificity 
to macrophages and DC subsets trigger intracellular signaling 
cascades that result in the secretion of interferons (IFNs) and pro-
inflammatory cytokines and activation of host defense programs 
necessary for innate or adaptive immune responses. The same 
cells also specifically express immunoreceptor tyrosine-based 
activation motif (ITAM)-associated receptors that can modulate 
TLR-signaling pathways (3, 8, 9). The conserved ITAM-signaling 
motif, with a consensus sequence YXXL/I–X6–8–YXXL/I (where 
X denotes any amino acid), is present in the cytoplasmic tail 
of transmembrane adaptor molecules associated with multiple 
receptors. Initially discovered ITAM-associated receptors, 
including the T-cell receptor, B-cell receptor (BCR), and Fc 
receptors (FcRs), were shown to induce phosphorylation of the 
tyrosines within the ITAMs, to recruit Syk tyrosine kinases, and 
to activate the immune cell. More recent studies have shown that 
some ITAM-associated receptors mainly in the innate immune 
cells efficiently inhibit downstream signaling triggered by other 
types of PRRs.
Here, we present an overview of molecular mechanisms 
acting at the crossroads of TLRs and regulatory receptors (RRs) 
signaling and address the question of how the engagement of the 
ITAM-associated receptors in macrophages and two subtypes of 
FiGURe 1 | Activatory signaling pathways control TLR7/9 signaling in plasmacytoid DCs (pDCs) (simplified view). (A) Ligation of TLR7 or TLR9 with their 
agonists, CpG-A or CpG-B, induces different types of signaling. Aggregating CpG-A is transported in the presence of adaptor protein 3 (AP3) to the interferon-
regulatory factor 7 (IRF7) endosomes, where a signalosome composed of IRAK1, IRAK4, TRAF3, and TRAF6 is formed. IRF7 signalosome activates production of 
interferons (IFNs)-I (IFN-α/β) and IFN-III (IFN-λ). In contrast, transcriptome studies showed that CpG-A downmodulates expression of some chemokine and cytokine 
receptors and MHC class II molecules (16). Monomeric CpG-B is transferred to the NF-κB endosomes, where a signalosome is formed from the set including 
IRAK4, TRAF6, transforming growth factor β-activated kinase 1 (TAK1), and NF-κB/MAPK/IRF5, which leads to maturation of pDCs and formation of pro-
inflammatory cytokines and chemokines. IRAK2 suppresses IFN-I/III production but positively controls production of pro-inflammatory cytokines (3, 5, 16). 
(B) Regulatory signaling pathways. Crosslinking of regulatory receptors, such as blood dendritic cell antigen 2 (BDCA-2), ILT-7, FcεRI, or NKp44, induces activation 
signals that lead to phosphorylation of tyrosines (shown by red circles) within the FcεRIγ immunoreceptor tyrosine-based activation motif (ITAM) and to recruitment of 
spleen tyrosine kinase (SYK) kinase. FcεRIγ-mediated B-cell receptor (BCR)-like signaling involving SYK, B-cell linker protein (BLNK), Bruton’s tyrosine kinase (BTK), 
and PLCγ results in hydrolysis of phosphatidylinositol 4,5-biphosphate to diacylglycerol (DAG) and inositol-1,4,5-triphosphate (InsP3). DAG activates protein kinase C 
(PKC) and mitogen-activated protein kinase (MAPK), which contribute to activation of activator protein (AP1) and NF-κB. InsP3 leads to transient release of 
intracellular Ca2+ stores followed by activation of calmodulin-dependent kinase (CAMK) and cyclic-AMP-responsive-element-binding protein. In parallel, calcineurin 
contributes to activation of the nuclear factor of activated T cells (NFAT). Transcriptome studies showed that BDCA-2 downmodulates expression of IFN-I, IFN-III, 
some chemokines and cytokines, and IFN-stimulated genes (16).
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translocates to the nucleus and, together with ATF-2, c-Jun, and 
nuclear factor kappa B (NF-κB) subunits p50 and RelA, initiates 
the transcription of IFN-I (12). Furthermore, it has been dem-
onstrated that TLR9-mediated induction of transforming growth 
factor β-activated kinase 1 (TAK1) and of inhibitor of nuclear 
factor κB kinase subunit β, followed by the IFN-β-stimulated 
activation of the JAK-STAT1/2 pathway, are essential for produc-
tion of IFN-α (13). This second loop of IFN-I signaling induced 
by IFN-β secreted by pDCs triggers a robust IFN-I/III response 
and expression of IFN-stimulated genes, and it can be blocked 
by mAbs against secreted IFN-I or IFN-α/β receptor. In contrast 
to IRF7-mediated production of IFN-I, monomeric CpG-B oli-
gonucletides are transferred to an endolysosomal compartment 
where they activate the MyD88–NF-κB pathway that triggers 
expression of mitogen-activated protein kinases (MAPKs) and 
IRF5 (14, 15) (Figure 1A). Both, NF-κB and MAPKs, stimulate 
secretion of chemokines and of the pro-inflammatory cytokines 
interleukin-6 and tumor necrosis factor-α (TNF-α) and stimulate 
4Hirsch et al. TLR and ITAM Signaling in Macrophages and DCs
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expression of co-stimulatory molecules, such as CD80 (B7.1) 
and CD86 (B7.2).
In addition to nucleotide-sensing TLRs, pDCs also recognize 
pathogens through a battery of cell surface RRs, including FcRs 
and LLRs. The principal function of these RRs on pDCs is to 
facilitate antigen capture and presentation and to prevent aber-
rant immune responses by modulating production of IFN-I and 
pro-inflammatory cytokines (3, 5, 11) (Figure 1B). RRs deliver 
their signal through immunoreceptor tyrosine-based inhibition 
motif (ITIM) or through ITAM-associated adaptors, like the 
γ-chain of FcεRIγ or DNAX activation protein 12 (DAP12). 
Among ITAM-signaling receptors, blood dendritic cell antigen 
2 (BDCA-2, CD303, CLEC4C) (17, 18), immunoglobulin-like 
transcript (ILT7, CD85g) (19, 20), and FcεRI (21) signal through 
FcεRIγ, while NKp44 (22) and mouse pDC–specific Siglec-H (23) 
signal through DAP12. In pDCs, triggering of these receptors ini-
tiates a signaling pathway involving spleen tyrosine kinase (SYK), 
Bruton’s tyrosine kinase, B-cell linker protein, phospholipase 
Cγ 2 (PLCγ2), MEK-ERK, and induction of intracellular Ca2+ 
mobilization, similar to the pathway that occurs downstream of 
the BCR (18). Despite the similarity with BCR pathway, BDCA-2 
signaling does not lead to the activation of the canonical NF-ĸB 
pathway monitored by the IĸBα (16). Other RRs of pDC, such as 
dendritic cell immunoreceptor (DCIR, CLEC4A) (24), contain 
an ITIM motif. In spite of differences in ITAM or ITIM motifs, 
all these receptors inhibit TLR7/9 signaling (17, 18). Thus, the 
production of IFN-I in pDCs is controlled positively by immu-
nogenic TLR7/9 and negatively by tolerogenic RRs.
Human cDCs, also called classical or myeloid dendritic cells, 
can be divided into at least two subsets. The more common mDC1s 
(BDCA-1+CD1c+), which produce inflammatory cytokines and 
chemokines, are major stimulators of T  cells (25). The second 
subset, extremely rare mDC2s (BDCA-3+ XCR1+Clec9A+) pro-
duce IL-12 and cross-present antigens for CD8 class I-restricted 
cytotoxic T lymphocytes (26, 27). cDCs detect invading microbes 
with the cell surface-expressed TLR1 and TLR2, which recognize 
peptidoglycan and lipoproteins, and endosomal compartment-
localized TLR3, which recognizes double-stranded (ds)RNA, 
and TLR8, which recognizes single-stranded RNA (3–5). mDC2s 
are major producers of IFN-III, induced via dsRNA-sensing 
TLR3 pathway, independent of TLR7 (27). Immature cDCs 
sample the surrounding microenvironment for pathogens by 
numerous PRRs, including TLRs and ITAM-associated LLRs 
(6, 28, 29). Among ITAM-associated LLR expressed on cDCs, 
Dectin 2 (CLEC6A) and macrophage-inducible C-type lectin 
(Mincle, CLEC4E) associate with the ITAM-containing adap-
tor FcRγ, while myeloid DAP12-associated lectin-1 associates 
with the adaptor DAP12. Ligand binding to these LLRs leads 
in cDCs to phosphorylation of ITAM and recruitment of 
SYK like in pDCs (Figure 1B). However, in contrast to pDCs, 
recruitment of SYK in cDCs is followed by the formation of 
SYK–CARD9–BCL9–MALT1 complex, activation of the NF-ĸB 
subunit c-Rel, and production of pro-inflammatory cytokines 
(4, 6, 30). Surprisingly, this signaling pathway can result in the 
IRF5-mediated production of IFN-β without engagement of 
TLRs (31). Previous report of an alternative mechanism based 
on recognition of fungal infection by TLR7, independently of 
Dectin-1, makes induction of IFN-β in cDCs the matter of debate 
(32). While ligation of ITIM-associated LLR, such as myeloid 
C-type lectin-like receptor (MICL) or DCIR in cDCs inhibits 
TLR4 and TLR8 signaling (24, 33, 34), suppression of TLR signal-
ing by ligation of ITAM-associated LLRs in cDCs has not been 
reported (28). These results together with the recent observation 
showing that Dectin-1-activated pDCs promote Th2-type T cell 
responses while Dectin-1-activated cDCs do the opposite, point 
to the importance of combination of PAMP, PRR, and the cell 
context in the regulation of adaptive immune responses by innate 
immunity (4, 35).
NeGATive SiGNALiNG BY  
iTAM-ASSOCiATeD ReCePTORS  
iN MACROPHAGeS
Results obtained during the two last decennia show that immune 
receptors associated with an ITAM can generate stimulatory or, 
paradoxically, inhibitory signals (36–44) (Figures 2A,B). These 
findings, obtained mostly in macrophages, provoked intense 
research into underlying mechanisms, as well as semantic 
debate (45). Inhibition can be readily explained by the paired co-
clustering of ITIM-bearing receptors with the targeted ITAM-
associated receptor, which brings them into close proximity for 
the consecutive inhibitory action of the tyrosine phosphatase 
SRC-homology-2 (SH2)-domain-containing protein tyrosine 
phosphatase 1 (SHP1) and SH2-domain-containing inositol 
phosphatase-1 (SHIP) (9, 24, 34, 42, 44) (Figure 2B). The work 
of several laboratories suggests that positive or negative control 
of immune responses, in the case of ITAM alone, is determined 
by avidity of ITAM-associated receptors to their ligands. The 
resulting “signal-switch hypothesis” is based on the observation 
that cross-linking by multimeric or high-avidity engagement of 
the ITAM-associated receptors leads to complete phosphoryla-
tion of ITAM tyrosine residues followed by the recruitment of 
SYK and to cell activation that synergizes IFN-I production, 
but inhibits cytokine signaling (8, 9, 39, 45, 46) (Figure  2A). 
In contrast, monovalent or low-avidity engagement of the 
ITAM-associated receptor results in monophosphorylation 
of the membrane-distal tyrosine (Y304) of ITAM allowing a 
transient recruitment and minimal activation of Syk (44) fol-
lowed by actin depolymerization and translocation of protein 
or lipid phosphatases (SHP1, SHIP) instead of SYK to the 
ITAM in lipid rafts. Tyrosine phosphatases SHP1/2 and lipid 
phosphatase SHIP recruited to partially phosphorylated ITAM 
can inhibit TLR4 signaling by dephosphorylation of signaling 
intermediates, but concomitantly cell sensitivity to extracellular 
cytokines increases (Figure 2B). If a high-avidity stimulation of 
other receptors, such as FcγRs, FcεRI, the tumor necrosis factor 
receptors, chemokine CC-motif receptor 2, or TLRs, occurs in 
the proximity of a weak-avidity stimulation, the high-avidity-
stimulated receptor is recruited toward the inhibitory SHP1 
(9, 38, 42, 43, 46, 47). High-avidity signaling is deactivated by 
SHP1 in rafts and completed after internalization and segregation 
into polarized clusters called “inhibisomes,” with SYK present at 
their periphery (9, 42).
FiGURe 2 | Continued  
High- and low-avidity engagement of the immunoreceptor tyrosine-
based activation motif (iTAM)-associated receptors in macrophages. 
(A) High-avidity ligation of the ITAM-associated receptor results in synergy of 
ITAM and TLR4 signaling. High-avidity ligation of macrophage receptors, 
such as Fc receptors (FcRs) or β2-integrin [e.g., by cross-linking of FcR with 
immune complexes (IC), or β2-integrin with CD11b mAb or poly arginine–
glycyl–aspartic acid (RGD) motifs (8)], induces activation signals that lead to 
phosphorylation of tyrosine residues within the DNAX activation protein 12 
(DAP12) ITAM motif and to recruitment of spleen tyrosine kinase (SYK) 
kinase. DAP12 ITAM-mediated signaling involving SYK, B-cell linker protein 
(BLNK), Bruton’s tyrosine kinase (BTK), and PLCγ proceeds as the signaling 
triggered by regulatory receptors in plasmacytoid DCs (Figure 1B). Ligation 
of TLR4 with its agonist (LPS) induces formation of a signalosome (from a set 
including IRAK1, IRAK4, TRAF3, and TRAF6), which activates IRF3 and 
production of IFN-β and pro-inflammatory cytokines (8, 9, 46). Tyrosine 
residues in ITAM motifs are shown by red circles. (B) Low-avidity ligation of 
the ITAM-associated receptor [e.g., by ligation of FcγR with monomeric IgG 
as exemplified by ligation of FcγRIIA with AT-10 F(ab′)2 (44), β2-integrin with 
CD11b F(ab′)2, or with Extracellular matrix (ECM) or triggering receptor 
expressed on myeloid cells 2 (TREM2) with semaphorin 6D] results in 
inhibition of TLR4 signaling. Low-avidity engagement of a high-affinity 
receptor results in recruitment of the SRC-homology-2 (SH2)-domain-
containing protein tyrosine phosphatase 1 (SHP1), SHP2, and SH2-domain-
containing inositol-5-phosphatase (SHIP) to the monophosphorylated 
membrane-distal tyrosine (Y304) of ITAM (44), shown by a letter P within a 
red circle. SHP1, SHP2, or SHIP can dephosphorylate TLR4 signaling 
intermediates. Low-avidity receptor ligation changes the balance between 
calcium and protein kinase C (PKC)-mediated pathways, leading to increased 
activity of calmodulin-dependent kinase (CAMK) and nuclear factor of 
activated T cells (NFAT) in the absence of NF-κB or mitogen-activated protein 
kinase activation.
FiGURe 2 | Continued
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inositol-1,4,5-triphosphate (InsP3) and low levels of diacylglycerol 
(Figure 2B). This imbalance results in triggering of constitutive 
calcium and MAPK signaling without phosphorylation of IκB 
at position Ser32 (47) and without activation of NF-κB, but it is 
sufficient to activate nuclear factor of activated T cells (8, 48). The 
importance of calcium signaling is highlighted by the finding that 
release of intracellular calcium activates the calcium-dependent 
phosphatase calcineurin, which is involved in the inhibition of 
TLR signaling by targeting the adaptor proteins MyD88 and 
TRIF (47).
A recent study showed that the TLR pathway in macrophages 
could be inhibited by another molecular mechanism, in which 
ITAM-associated low-avidity signaling inactivates MyD88 (49) 
(Figure  3). In this mechanism, SRC kinases-activated SYK 
phosphorylates Tyr227 on MyD88 and Tyr375 on TRIF, which 
function as substrates of the E3 ubiquitin ligase Cbl-b activated by 
β2-integrin CD11b (integrin αM, Mac1). The role of β2-integrin in 
this interplay depends on the orientation of outside-in and inside-
out signals. In inside-out signaling, TLR4 activates β2-integrin 
through PI3K and effector RapL by phosphorylation of the β2-
integrin DAP12 adaptor ITAM, which attracts SYK (Figure 3A) 
and leads to separation of the cytoplasmic domains α and β of 
β2-integrin (Figure 3B). Then, in outside-in signaling, the acti-
vated β2-integrin engaged or not with a low-avidity ligand feeds 
back to inhibit TLR4 signaling by activation of SYK-mediated 
phosphorylation of MyD88 and TRIF, which are subsequently 
ubiquitinated by Cbl-b and degraded (49). Several reports have 
shown that upon low-avidity β2-integrin stimulation, Cbl-b 
MeCHANiSMS iNHiBiTiNG TLR 
SiGNALiNG iN MACROPHAGeS
Spatiotemporal compartmentalization of inhibitory ITAM-
containing receptors into lipid rafts is a key event in the trig-
gering of several ITAM-mediated inhibitory signals. Thus, the 
presence of ITAMs in inhibisome rafts can be responsible for 
induction of a phosphatidylinositol 3-OH kinase (PI3K)- and 
PLCγ2-mediated imbalance characterized by accumulation of 
FiGURe 3 | Low-avidity signaling of β2-integrin regulates toll-like 
receptors (TLR) signaling in macrophages. (A) Inside-out signals are 
initiated by TLR4 activation through phosphatidylinositol 3-OH kinase (PI3K) 
and effector RapL β2-integrin by separation of the cytoplasmic domains of 
α- and β-integrin chains. (B) β2-integrin signals in a low-avidity (without even 
ligand binding) outside-in manner through ITAM-associated activation of the 
spleen tyrosine kinase (SYK) pathway, which induces phosphorylation of Tyr227 
on MyD88 and of Tyr375 on TRIF. TLR4 signaling is regulated by Cbl-b-
mediated degradation of MyD88 and TRIF. Skewed position of β2-integrin 
indicates conformational changes after separation of the cytoplasmic domains 
α and β. (C) Cbl-b associates with CD2-associated protein (CD2AP, CIN85) 
and enhances the ubiquitination and degradation of SYK and FcεRIγ. 
Ubiquitinated MyD88 and TRIF are degraded by the proteasome.
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associates with CD2-associated protein (CIN85) and enhances 
the ubiquitination and degradation of SYK and FcεRIγ, resulting 
in inhibition of RRs (BCR-like) signaling (49–52) (Figure 3C). It 
has been reported that activation of SYK at the plasma membrane 
suppresses the TRAF6- and TAK1-mediated pro-inflammatory 
pathway and in contrast enhances the production of IFN-I via 
TBK-1 and IRF3 activation (53, 54). Thus, the global activation 
status of the target cell will be responsible for the outcome of TLR 
signaling.
In contrast to the well-established role of MAPK in activation 
of IFN-β production, several recent reports highlight suppres-
sive aspects of MAPK signaling in myeloid cells (41, 43, 55–59). 
A central regulator that modulates repartition of MAPK signaling 
is Tumor Progression Lokus 2 (TPL-2 or Map3k8). TPL-2 down-
modulates production of IFN-β and IL-12 (57) in macrophages, 
while it induces production of TNF-α (60) and IL-1β (61). It 
has been shown that activation of the MAPK (ERK) pathway by 
TPL-2 results, in macrophages but not in pDCs, in transloca-
tion of c-Fos into the nucleus and in inhibition of IFN-β gene 
transcription (57).
HiGH-AviDiTY eNGAGeMeNT OF THe 
iTAM-ASSOCiATeD RRs iN pDCs iNHiBiTS 
TLR7/9 SiGNALiNG
A cornerstone of the signal-switch hypothesis in macrophages is a 
direct relation between the avidity of the ITAM-associated recep-
tor engagement and the intensity of IFN-I production (8, 9, 39, 
45, 46). Surprisingly, in pDCs, the high-avidity cross-linking of 
BDCA-2 with mAb, as documented from protein tyrosine phos-
phorylation, activation of PLCγ, and intracellular Ca2+ release, 
results in the attenuation of TLR7/9-induced production of IFN-
α and pro-inflammatory cytokines (17, 18) (Figure 4). As we and 
others demonstrated in pDCs, in contrast to macrophages, low-
avidity engagement of BDCA-2 with monovalent anti-BDCA-2 
Fab fragment, which does not induce any protein tyrosine 
phosphorylation in pDCs, fails to inhibit IFN-α production (62). 
As with BDCA-2, it is also the case that high-avidity engagement 
of the FcεRIγITAM-associated receptor ILT7 or FcεRIα, or of the 
DAP12ITAM-associated natural cytotoxicity receptor NKp44, is 
accompanied by protein tyrosine phosphorylation, calcium 
influx, and inhibition of IFN-I and pro-inflammatory cytokine 
production (19–22, 63). In addition to cross-linking with mAbs, 
high-avidity engagement of ILT7 with its natural ligand, bone 
marrow stromal cell antigen 2 (BST2, also called CD317, tetherin, 
or HM1.24) (19, 20, 63); of BDCA-2 with HIV-1 gp120 (64) or 
hepatitis C virus E2 glycoprotein (65); and of NKp44 with pro-
liferating cell nuclear antigen also result in inhibition of IFN-I 
production (66).
The mechanism explaining inhibition of TLR7/9 signaling by 
high-avidity engagement of the ITAM-associated receptors in 
pDCs is not clear. The principal difference between pDCs and 
macrophages could reside in the localization and timing of the 
early steps of interaction of TLRs and ITAM-associated recep-
tors. While in macrophages, the TLR4 and the ITAM-mediated 
β2-integrin signaling are concomitantly triggered from a close 
FiGURe 4 | High-avidity engagement of the immunoreceptor 
tyrosine-based activation motif (iTAM)-associated receptors in 
plasmacytoid DCs (pDCs) inhibits TLR7/9 signaling. (A) In immature 
pDCs, blood dendritic cell antigen 2 (BDCA-2) and CD32a (FcγRIIa) are 
expressed on the cell surface. Homeostatic levels of TLR7/9 are present in 
endosomes. (B) BDCA-2 mAb or HIV-1 gp120/anti-gp120 Ab complex 
simultaneously engages BDCA-2 and CD32a, leading to internalization of 
both receptors. Crosslinking of BDCA-2-induces B-cell receptor (BCR)-like 
ITAM-mediated signaling. BDCA-2 cross-linking induces formation CD2AP/
SHIP1 complex, which inhibits the Cbl-b-induced ubiquitination of spleen 
tyrosine kinase (SYK), FcεRIγ, and FcγRIIa and maintains the expression 
levels of SYK and FcεRIγ.
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vicinity in the lipid raft (Figure 3), in pDCs, the TLR7/9 signal-
ing is triggered from an endosome, whereas ITAM-mediated 
RRs signaling is triggered from the plasma membrane, with an 
unknown delay. Earlier findings suggested that in unstimulated 
pDCs, TLR7 and TLR9 reside in the endoplasmic reticulum 
and are delivered to the endolysosomal compartment only 
after uptake of RNA or DNA ligands to endosomes (10, 67, 68). 
However, more recent studies have demonstrated a steady-state 
flow of TLR9 from endoplasmic reticulum to endolysosomes, 
where TLR9 is present in the mature, cathepsin-cleaved form 
(69, 70) (Figure 4A). Most of these studies were performed in 
mouse bone marrow-derived macrophages, and parallel experi-
ments in B  cells showed that TLR9 trafficking is cell-context-
dependent, making an actual localization of TLR7/9 in pDCs a 
matter of debate (69, 70). As with TLR9 trafficking, trafficking 
of RRs in pDCs remains elusive. Formation of the antibody–
BDCA2 receptor complex (17), which colocalizes with EEA1 
in early endosomes 5–10 min after crosslinking of BDCA2, was 
demonstrated in several laboratories (71, 72). Results from our 
laboratory have shown that 2 min after crosslinking of BDCA-2, 
SYK is phosphorylated, without assigning the phosphorylation 
to plasma membrane or endosome (73) (Figure  4B). Whether 
TLR7/9 and BDCA-2 co-localize in endolysosomes (71, 72), and 
at what level, remains to be determined.
As in macrophages, ubiquitination of MyD88, SYK, and 
FcεRIγ could play a crucial role in the outcome of TLR7/9 and RRs 
signaling in pDCs. Ubiquitination of these molecules depends 
on the cellular context. It has been shown that upon BDCA2 
cross-linking in human pDCs, CD2AP forms a complex with 
SHIP1 and Cbl-b with reduced Cbl-E3 ubiquitin ligase activity in 
comparison with CD2AP- or SHIP1-knocked-down pDCs (3, 74) 
(Figure 4B). The CD2AP/SHIP1/Cbl complex is then recruited 
to the plasma membrane, where it co-localizes with cross-linked 
BDCA2/FcεR1γ complex. Inhibition of the Cbl-b-induced ubiq-
uitination and degradation of FcεR1γ and SYK by the CD2AP/
SHIP1 complex results in upregulation of BCR-like signaling 
and inhibition of TLR7/9 signaling. Although these results were 
not reproduced in mouse pDCs (75), differences between the 
triggering of TLR and ITAM signaling in macrophages and in 
pDCs (Figures  1 and 2) might be responsible for preferential 
ubiquitination of MyD88, SYK, and FcεRIγ in these cells.
In addition to ITAM-associated RRs, pDCs express an 
ITAM-associated FcR, FcγRIIa (CD32a), which is responsible 
for uptake and delivery of systemic lupus erythematosus (SLE) 
immune complexes (IC) in the endosomal compartment called 
the IFN signaling compartment, from where they trigger TLR9 
signaling followed by massive IFN-I production (72, 76). ITAM-
associated CD32a and ITIM-associated CD32b are the only FcRs 
on pDCs (72, 76). Surprisingly, BDCA-2 mAb simultaneously 
ligates BDCA-2 with F(ab′)2 and CD32a with the Fc region of 
the same single BDCA-2 mAb molecule, leading to the con-
current internalization of BDCA-2 and CD32a (Figure  4B). 
Simultaneous engagement of BDCA-2 and CD32a with complete 
BDCA-2 mAb, in contrast to ligation with F(ab′)2, synergizes 
inhibition of TLR9 signaling triggered by FcR-dependent SLE IC. 
However, simultaneous engagement does not potentiate inhibi-
tion of TLR7/9 signaling triggered by FcR-independent agonists 
CpG-A, CpG-B, and R848 (72). Thus, the latter results do not 
lend any support to the hypothesis that the simultaneous ligation 
of BDCA-2 and CD32a with a single mAb molecule, creating a 
trimolecular complex, would be responsible for BDCA-2 mAb-
mediated inhibition of TLR9 signaling and IFN-I production (9, 
38, 46, 47, 72). The synergistic effect of simultaneous engagement 
of CD32a and BDCA-2 highlights the therapeutic potential of 
these mAbs for inhibition of IFN-I production and for treat-
ment of autoimmune diseases, such as SLE. Next, experiments 
can show whether natural ligands of RRs, such as BST2, HIV-1 
gp120, hepatitis C virus E2 glycoprotein, or their complexes with 
antibody could cross-link BDCA-2/ILT7 and CD32a and inhibit 
TLR7/9 signaling (Figure 4B).
TOLeROGeNiC eFFeCT OF THe  
HiGH-AviDiTY eNGAGeMeNT OF  
iTAM-ASSOCiATeD ReCePTORS iN pDCs
Antigen targeted to pDCs by means of BDCA-2 mAb is rapidly 
endocytosed and traffics via early endosomes to MHC-enriched 
TABLe 1 | Cross talk between immunoreceptor tyrosine-based activation motif (iTAM)-signaling and toll-like receptors (TLR) pathways in macrophages 
and plasmacytoid DCs (pDCs).a
TLR iTAM-coupled receptors iTAM/TLR cross talk
Receptor Ligand Receptor Adaptor Ligand High-avidity  
ligation
Low-avidity 
ligation
High avidity Low avidity
Macrophage TLR4 LPS β2-Integrin
FcγRI
FcγRIIA
FcαR
FcεRI
TREM2
DAP12 Fibrinogen
IC/RF
IC/RF
IC/RF
IC/RF
poly RGD
ECM
Monomeric IgG 
or IgA, IVIg, mAb 
F(ab′)2
Semaphorin 6D
•	 Synergizes TLR  
signaling
•	 Inhibits cytokine  
signaling
•	 Activation
•	 Inhibits TLR 
signaling
•	 Enhances 
cytokine 
signaling
•	 Homeostasis
FcRγ
–
FcRγ
FcRγ
DAP12
pDCs TLR7 ssRNA
Resiquimod
BDCA-2 FcεR1γ HIV gp120,  
HCV E2; mAb
mAb Fab, F(ab′)2 •	 Inhibits TLR signaling
•	 Inhibits pDC maturation  
and T cell stimulation
•	 Homeostasis/anergy
No/unknown 
effect
ILT7 FcεR1γ BST2
FcεRIα FcεR1γ IgE
TLR9
NKp44 DAP12 PCNA
CpG ODNs Siglec-H DAP12 Sialic acid
FcγRIIA – IC
amAb, mAb Fab, and mAb F(ab′)2 are related to the respective receptor.
IC, immune complexes; RF, rheumatoid factor; IVIg, intravenous immunoglobulin; TREM2, triggering receptor expressed on myeloid cells 2; ECM, extracellular matrix; RGD, arginine–
glycyl–aspartic acid motif; DAP12, DNAX activation protein 12; BDCA-2, blood dendritic cell antigen 2; ILT7, immunoglobulin-like transcript; PCNA, proliferating cell nuclear antigen.
FiGURe 5 | Cross talk between immunoreceptor tyrosine-based 
activation motif (iTAM)-associated receptor signaling and toll-like 
receptor (TLR) pathways in conventional dendritic cells (cDCs), MΦ, 
and plasmacytoid DCs (pDCs): an iTAM-centric view. ITAM-mediated 
activation pathways are shown by green arrows; ITAM-mediated inhibitory 
pathways are shown by red lines. Positive or negative control of immune 
responses in macrophages (MΦ) is determined by avidity of ITAM-associated 
receptors to their ligands. Production of interferons (IFNs)-I is facilitated by 
interferon-regulatory factor 3 (IRF3) in macrophages, by IRF5 in cDCs, and by 
IRF7 in pDCs. In cDCs, ITAM-associated receptor signaling can result in the 
IRF5-mediated production of IFN-β without engagement of TLRs (31). 
Alternative pathway in cDCs (32) is shown by dotted arrow.
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by BDCA-2 cross-linking. Mature pDCs are characterized by the 
upregulation of CD40 and co-stimulatory molecules, including 
CD80 and CD86. Recent results have shown that BDCA-2 mAb 
cross-linking inhibits CpG-A and CpG-B-induced upregulation 
of co-stimulatory molecules CD40 and CD86 (62, 77–79). In 
contrast, CD40L-stimulated upregulation of CD86 in pDCs is 
unaffected by BDCA-2 cross-linking. These results suggest that 
BDCA-2 signaling interferes with TLR9 signaling in pDCs but 
probably not with T-cell-dependent pDC activation via CD40-
ligand (62). Actually, pDCs efficiently cross-present exogenous 
antigens to CD8+ T cells (80). Also, BDCA-2 agonist HIV-1 gp 
120, but not the natural agonist of ILT7, BST2, suppressed TLR9-
mediated expression of co-stimulatory molecules CD80 and 
CD86 by pDCs (19, 64).
The capacity of pDCs to produce IFN-I and their central role at 
the interface of innate and adaptive immunity could make them 
important actors in antitumor immunity (81). However, recent 
evidence suggests that tumor-associated (TA) pDCs recruited in 
breast and ovarian tumors are dysfunctional and their presence 
in these tumors is a negative prognostic factor for overall survival 
(82–84). This dysfunctionality is characterized by impairment of 
their IFN-I secretion and by strong expression of ICOS ligand, 
which leads to induction of immunosuppressive regulatory T cells 
(Treg) and priming of IL-10-secreting CD4+ T  cells (82, 83). 
Apart from tumor-derived soluble immunosuppressive factors, 
such as TNF-α and TGF-β (85), recent data suggest that TA-pDC 
impairment could also result from the interaction of ITAM-
associated RRs of pDCs with their ligands expressed on cancer 
cells, such as BST2 (20). Recent data from the C. Caux laboratory 
have shown that mAbs against ICOS inhibit TA-Treg expansion 
and IL-10 secretion, demonstrating a pivotal role of TA-pDCs 
in the immunosuppressive mechanism (82, 83). Collectively, 
these results indicate that a tumor microenvironment induces a 
tolerogenic character in pDCs.
endosomes independently of TLR7/9 stimulation (71). However, 
the next steps of antigen presentation, including restimulation 
of antigen-specific CD4+ effector memory T helper cells, are 
dependent on TLR7/9 stimulation of pDCs, which is inhibited 
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CONCLUDiNG ReMARKS
Fifteen years after the discovery of the inhibitory role of BDCA-2 
in IFN-I production in pDCs (17), its molecular mechanism 
remains elusive. The signal-switch hypothesis had a seminal role 
in the understanding of cross-regulation of cytokine- and TLR-
signaling pathways in macrophages (8, 9, 28, 39, 58). However, 
further studies showed that the ITAM-signaling pathway may be 
regulated in a special way in human pDCs (11, 18–20). While 
the high-avidity engagement of ITAM-associated receptors in 
macrophages leads to potentiation of TLR signaling, it results 
in the attenuation of TLR-induced IFN-I production in pDCs 
(Figure  5; Table  1). Surprisingly, few data are available on the 
interplay of ITAM-associated receptors and TLRs in cDCs. 
Cellular context, spatiotemporal differences, and different func-
tions of ITAM-associated receptors could be responsible for the 
different interplay of ITAM and TLR pathways in pDCs, cDCs, 
and macrophages.
Published data suggest that ITAM-associated receptors play 
different roles in pDCs, cDCs, and in macrophages. Under home- 
ostatic conditions in macrophages, the ITAM-associated 
receptors enable a fine-tuning of immune responses, includ-
ing inhibition of IFN-I production and high sensitivity to 
extracellular cytokines. In an infection setting, ITAM-associated 
receptors in macrophages switch to signaling for robust pro-
duction of cytokines including IFN-I, to cell activation and to 
low sensitivity to extracellular cytokines. In cDCs, ligation of 
ITAM-associated receptors leads to rapid activation of NF-ĸB 
and massive production of cytokines, which can occur without 
engagement of TLR. In contrast, the major role of ITAM-
associated RRs in pDCs is related to inhibition of cytokine 
production and reestablishment of a tolerogenic state following 
pDC activation. Limitation of the ITAM-associated RR signaling 
in pDCs to high-avidity engagement could be related to a low 
homeostatic level of TLR7/9 in endosomes in immature pDCs 
under physiological conditions (10, 70). The low homeostatic 
level of TLR7/9 in endosomes in immature pDCs could reduce 
the risk of undesirable triggering of IFN-I signaling to the same 
extent as that of the inhibition of IFN-I induced in macrophages 
by tonic ITAM signaling. Also, simultaneous engagement of 
BDCA-2 and CD32a leading to the internalization of both 
receptors is consistent with the tolerogenic role of BDCA-2. 
Differential effects of ITAM-mediated signaling in pDCs and 
macrophages would promote a coordinated cellular response 
to infection and inflammation.
Interaction of the TLR pathway and ITAM signaling in 
pDCs plays an important role in control of the innate immune 
responses in viral infections (1, 64, 65), cancer proliferation 
(20, 83, 84), and autoimmune diseases (54, 86). Understanding 
the ITAM/TLR-signaling network in pDCs may serve as an 
effective means for positive and negative control of pDC activa-
tion. Progress in understanding these interactions paves the 
way for the development of compounds to control activation 
of pDCs. Pharmacologic targeting of TLR and ITAM signaling 
is thus an attractive new therapeutic approach for treatment of 
chronic infections, cancer, and autoimmune and inflammatory 
diseases.
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